"Imagine if the patient of the MoCA < 22 had the same number as MoCA >=26, 86 for ABL and 101 for placebo. Would we have gotten the same results of 158% relative improvement in cognitive function over the top standard of care placebo with statistical significance P-Value of 0.02? Was the MoCA <22, with 30 patients of ABL and 45 on placebo powered enough to prove absolute efficacy?"

Regardless, the cognition sub-study was only an exploratory study, never designed to support regulatory approval for a stand alone cognition indication. 

BDAZ